The present invention relates to a novel two-component system comprising acetylsalicylic acid (ASA) and which is particularly useful in providing an aqueous solution of ASA for immediate peroral administration.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

The present invention relates to the compositions containing dicycloplatin, pharmaceutical use of the compositions in the treatment and/or prevention of pain, inflammation and virus-related diseases, and methods of preparing the compostions thereof.

The invention relates to a novel process for preparing Spiro derivatives, in particular 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, and to novel intermediates for use in said process along with processes for preparing said intermediates.

The invention relates to a novel process for preparing Spiro derivatives, in particular 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, and to novel intermediates for use in said process along with processes for preparing said intermediates.

Disclosed herein is an overbased alkaline earth metal hydrocarbyl-substituted salicylate detergent comprising both carbonate and borate moieties and exhibiting the following characteristics: a basicity index of at least 3.8; a ratio of soap content to mass % boron is greater than 55 mmol/kg; a soap content of at least 330 mmol/kg; a TBN, measured according to ASTM D2896, of at least 220 mg KOH/g; and a mass ratio of borate to carbonate from 0.75 to 6.0, wherein the alkaline earth metal comprises calcium and/or magnesium, and the hydrocarbyl substitution comprises 9 to 30 carbon atoms. Methods of making the boron-containing salicylate detergent, specifically to be package-stable, are also disclosed, as well as package-stable lubricant additive package concentrates and lubricating oil compositions containing same.

Disclosed herein is an overbased alkaline earth metal hydrocarbyl-substituted salicylate detergent comprising both carbonate and borate moieties and exhibiting the following characteristics: a basicity index of at least 3.8; a ratio of soap content to mass % boron is greater than 55 mmol/kg; a soap content of at least 330 mmol/kg; a TBN, measured according to ASTM D2896, of at least 220 mg KOH/g; and a mass ratio of borate to carbonate from 0.75 to 6.0, wherein the alkaline earth metal comprises calcium and/or magnesium, and the hydrocarbyl substitution comprises 9 to 30 carbon atoms. Methods of making the boron-containing salicylate detergent, specifically to be package-stable, are also disclosed, as well as package-stable lubricant additive package concentrates and lubricating oil compositions containing same.